ArticleNucleic acids research2026
Single-residue engineering of Klenow fragment enables broad acceptance of chemically modified nucleotides.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Xeno nucleic acids (XNAs) exhibit enhanced chemical stability and significant resistance to nuclease degradation, making them attractive for synthetic biology and therapeutic development. Most engineered XNA polymerases are derived from thermophilic organisms and exhibit limited catalytic activity under physiological conditions, thereby limiting their broader application. We report a single-residue mutant (F762A) of the mesophilic Family A DNA polymerase I Klenow fragment that synthesizes DNA, RNA, 2'-F-RNA, and FANA with yields exceeding 85% at 37°C, as well as 2'-OMe-RNA, HNA, phosphorothioate-, and (methyl) pseudoU-containing oligonucleotides, confirming its broad substrate compatibility. Compared to wild-type, F762A exhibits up to 90-fold higher catalytic efficiency for modified nucleotides while maintaining an overall error rate below 1.19 × 10-3. F762A functions efficiently under physiological metal ion concentrations and molecular crowding, with reverse transcriptase activity and 2'-F-RNA-templated self-replication. Unlike thermophilic XNA polymerases, nearly inactive at 37°C, F762A also extends DNA and RNA primers to generate chimeric XNAs. Molecular dynamics simulations show F762A relieves steric hindrance from the phenylalanine side chain, improving modified nucleotide accommodation while maintaining polymerase structural integrity. These findings establish a foundation for polymerase-mediated XNA synthesis under physiological conditions and expand the potential of XNAs in synthetic biology and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.